Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project
- PMID: 36316811
- PMCID: PMC9988328
- DOI: 10.1002/pbc.30054
Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project
Abstract
Background: Outcomes for patients with INRGSS metastatic special (MS) metastatic pattern neuroblastoma at initial diagnosis are well described. Prognosis after an initial event (relapse, progression, secondary malignancy) is unclear.
Methods: We investigated characteristics of MS pattern neuroblastoma patients in the International Neuroblastoma Risk Group database who subsequently experienced an event. Post-event overall survival (OS) ± standard error was calculated overall and by diagnosis era: before 2000 versus 2001 or after. Cox models were used to identify factors prognostic of post-event OS.
Results: Among 209 patients with an event, 88% were less than 365 days old at diagnosis; tumors were MYCN amplified in 24% and diploid in 33%. The median (range) time from diagnosis to first event was 8.16 months (7 days to 11.24 years). Of 96 patients with known relapse/progression pattern, 75% were metastatic or primary plus metastatic. Five-year post-event OS was 53% ± 3.6% and was higher for 2001 and afterwards (62% ± 5.0%) compared to before 2001 (44% ± 4.9%; p = .0046). In patients diagnosed in 2001 and after, older age, Hispanic ethnicity, MYCN amplification, 1p LOH, diploidy, high Mitotic Karyorrhexis Index, high lactate dehydrogenase (LDH), unfavorable histology, and longer time to first event were prognostic of worse post-event OS. Independent adverse prognostic factors on multivariable testing were non-White race, MYCN amplification, and diploidy.
Summary: Patients diagnosed in and after 2001 have substantially better post-event OS compared to before 2001. In those diagnosed in and after 2001, most well-accepted prognostic factors for OS at diagnosis are also prognostic of post-event OS. Future studies may evaluate strategies to improve outcomes in this rare population.
Keywords: INRGSS stage MS; neuroblastoma; prognosis; relapse.
© 2022 Wiley Periodicals LLC.
Figures











Similar articles
-
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.J Clin Oncol. 2020 Nov 1;38(31):3685-3697. doi: 10.1200/JCO.18.02132. Epub 2020 Sep 9. J Clin Oncol. 2020. PMID: 32903140 Free PMC article.
-
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.J Clin Oncol. 2009 Jan 20;27(3):365-70. doi: 10.1200/JCO.2008.17.9184. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047282 Free PMC article.
-
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.Pediatr Blood Cancer. 2014 Nov;61(11):1932-9. doi: 10.1002/pbc.25134. Epub 2014 Jul 7. Pediatr Blood Cancer. 2014. PMID: 25044743
-
Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.Pathol Int. 2021 Apr;71(4):232-244. doi: 10.1111/pin.13085. Epub 2021 Mar 3. Pathol Int. 2021. PMID: 33657257 Review.
-
Updates on liquid biopsies in neuroblastoma for treatment response, relapse and recurrence assessment.Cancer Genet. 2024 Nov;288-289:32-39. doi: 10.1016/j.cancergen.2024.09.001. Epub 2024 Sep 3. Cancer Genet. 2024. PMID: 39241395 Review.
Cited by
-
Epidemiology and clinical features of childhood malignant solid tumors in a single center in southwest China over 24 years.BMC Pediatr. 2025 Jan 7;25(1):12. doi: 10.1186/s12887-024-05360-3. BMC Pediatr. 2025. PMID: 39773427 Free PMC article.
-
Extracting Electronic Health Record Neuroblastoma Treatment Data With High Fidelity Using the REDCap Clinical Data Interoperability Services Module.JCO Clin Cancer Inform. 2024 May;8:e2400009. doi: 10.1200/CCI.24.00009. JCO Clin Cancer Inform. 2024. PMID: 38815188 Free PMC article.
-
Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions.Front Cell Dev Biol. 2024 Mar 27;12:1353860. doi: 10.3389/fcell.2024.1353860. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38601081 Free PMC article. Review.
-
Epidemiological and clinical characteristics of children with peripheral neuroblastic tumors: a study on a Moroccan population.J Cancer Res Clin Oncol. 2023 Dec;149(20):18023-18027. doi: 10.1007/s00432-023-05502-7. Epub 2023 Nov 18. J Cancer Res Clin Oncol. 2023. PMID: 37979055 Free PMC article.
-
FTO diversely influences sensitivity of neuroblastoma cells to various chemotherapeutic drugs.Front Pharmacol. 2024 Sep 4;15:1384141. doi: 10.3389/fphar.2024.1384141. eCollection 2024. Front Pharmacol. 2024. PMID: 39295930 Free PMC article.
References
-
- D’Angio GJ, Evans AE, and Koop CE, Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet, 1971. 1(7708): p. 1046–9. - PubMed
-
- Evans AE, D’Angio GJ, and Randolph J, A proposed staging for children with neuroblastoma. Children’s cancer study group A. Cancer, 1971. 27(2): p. 374–8. - PubMed
-
- Katzenstein HM, et al., Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol, 1998. 16(6): p. 2007–17. - PubMed
-
- Brodeur GM, et al., Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol, 1993. 11(8): p. 1466–77. - PubMed
-
- Brodeur GM, et al., International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol, 1988. 6(12): p. 1874–81. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical